Skip to content

Prevalence of the Metabolic Syndrome in SPR Taking Antipsychotics

Prevalence of the Metabolic Syndrome in Patients With Schizophrenia Taking Antipsychotics

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00569504
Enrollment
1000
Registered
2007-12-07
Start date
2007-12-31
Completion date
2009-09-30
Last updated
2009-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic Syndrome, Schizophrenia

Keywords

schizophrenia, antipsychotics, metabolic syndrome, prevalence

Brief summary

The purpose of this study is to assess the cross-sectional prevalence of the metabolic syndrome in patients with schizophrenia taking antipsychotics.

Detailed description

Schizophrenic patients taking any kind of antipsychotics for at least 1 year at the Seoul National Hospital will be participated in this study. we are planning to enroll approximately 1000 patients with schizophrenia. For each subject * abdominal circumference * body mass index * lipid profile : TG, HDL-chlo, total chol * systolic/diastolic blood pressure * fasting blood glucose will be measured. we will calculate the rates of patients who meet the criteria for the Metabolic syndrome. 1. Abdominal obesity : absolute criteria 2. 2 or more of followings 1. Triglyceride ≥ 150mg/dL or ongoing treatment 2. HDL-cholesterol \< 40mg/dL (men) HDL-cholesterol \< 50mg/dL (female) or ongoing treatment 3. Hypertension 130mmHg ≥ systolic 85mmHg ≥ diastolic or ongoing treatment 4. FBS ≥ 100mg/dL or previous diagnosis of type II DM

Interventions

None listed

Sponsors

Korea Otsuka Pharmaceutical Co., Ltd.
CollaboratorINDUSTRY
Seoul National Hospital
Lead SponsorOTHER_GOV

Study design

Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Patients taking a same antipsychotics at least more than one year * schizophrenia or schizoaffective disorder

Exclusion criteria

* none

Design outcomes

Primary

MeasureTime frame
metabolic syndromecross-sectional

Secondary

MeasureTime frame
each factor of metabolic syndrome

Countries

South Korea

Contacts

Primary ContactShi Hyun Kang, M.D.
drshe@hanmail.net82-2-2204-0326

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026